Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study

Table 2 Baseline variables and change of hepatitis B surface antigen in weeks 12 and 24 associated with hepatitis B surface antigen clearance

Predictors	Univariate analysis			Multivariate analysis
	OR	95%CI	P value	OR	95%CI	P value
Gender	2.045	(0.792-5.283)	0.149	-	-	-
ALT in IU/L	0.997	(0.968-1.027)	0.852	-	-	-
FibroScan value in kPa	0.794	(0.549-1.125)	0.803	-	-	-
BMI in kg/cm2	0.962	(0.951-1.218)	0.794	-	-	-
NA	1.790	(0.758-4.225)	0.184	-	-	-
Mode of HBV transmission	0.840	(0.298-2.372)	0.742	-	-	-
Age, yr	0.924	(0.878-0.972)	0.002	0.946	(0.833-0.981)	0.025
Baseline HBsAg as log10 IU/mL	0.371	(0.194-0.711)	0.003	0.557	(0.206-0.827)	0.019
Week 12 HBsAg as log10 IU/mL	0.273	(0.157-0.474)	< 0.001	0.542	(0.194-0.792)	0.002
Week 24 HBsAg as log10 IU/mL	0.218	(0.117-0.405)	< 0.001	0.188	(0.058-0.410)	0.004
HBsAg decline as log10 IU/mL
From baseline to week 12	10.646	(3.776-25.018)	< 0.001	8.925	(3.376-17.226)	< 0.001
From baseline to week 24	7.045	(3.223-15.400)	< 0.001	8.830	(4.553-18.213)	< 0.001
ALT ≥ 2 × ULN in the first 12 wkF1	4.182	(1.691-10.340)	0.002	5.275	(3.324-11.823)	0.014

^F1ALT ≥ 2 × ULN during the first 12 wk of therapy. ALT: Alanine aminotransferase; BMI: Body mass index; NA: Nucleoside Analogue or nucleotide analog; HBV: Hepatitis B virus; ULN: Upper limit of normal; OR: Odds ratio; CI: Confidence interval; UI: International unit.